Anita K. Dunbier

TL;DR: This study confirmed the performance of RS in postmenopausal HR+ patients treated with tamoxifen in a large contemporary population and demonstrated that RS is an independent predictor of DR in N0 and N+ hormone receptor-positive patientstreated with anastrozole, adding value to estimates with standard clinicopathologic features.

TL;DR: ROR provides more prognostic information in endocrine-treated patients with ER-positive, node-negative disease than RS, with better differentiation of intermediate- and higher-risk groups.

TL;DR: The hypothesis that CDH1 promoter methylation might function as the ‘second genetic hit’ in the genesis of gastric cancers in individuals with hereditary diffuse gastric cancer was suggested.

TL;DR: This prospective comparison study compared the prognostic ability of the breast-cancer index (BCI) assay, 21-gene recurrence score (Oncotype DX), and an immunohistochemical prognostic model (IHC4) for both early and late recurrence in patients with oestrogen-receptor-positive, node-negative breast cancer who took part in the Arimidex, Tamoxifen, Alone or in Combination clinical trial.

TL;DR: The identified an estrogen-independent role for ER and the CDK4/Rb/E2F transcriptional axis in the hormone-independent growth of breast cancer cells and their combination with PI3K inhibitors for treatment of antiestrogen-resistant breast cancers.